CFGS
NBIX icon

Concourse Financial Group Securities’s Neurocrine Biosciences NBIX Stock Holding History

Concourse Financial Group Securities’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-669
Closed -$98.2K – 1338
2024
Q4 		$98.2K Buy
669
+8
+1% +$989 0.01% 948
2024
Q3 		$76.2K Sell
661
-8
-1% -$1.1K ﹤0.01% 1033
2024
Q2 		$92.1K Buy
669
+71
+12% +$9.74K 0.01% 955
2024
Q1 		$82.5K Buy
598
+47
+9% +$6.42K 0.01% 990
2023
Q4 		$72.6K Buy
551
+103
+23% +$11.9K 0.01% 999
2023
Q3 		$50.4K Buy
448
+150
+50% +$15.8K ﹤0.01% 1078
2023
Q2 		$28.1K Sell
298
-270
-48% -$26.4K ﹤0.01% 1330
2023
Q1 		$57.5K Sell
568
-8
-1% -$832 ﹤0.01% 1043
2022
Q4 		$68.8K Sell
576
-307
-35% -$36K 0.01% 953
2022
Q3 		$94K Sell
883
-400
-31% -$40.6K 0.01% 743
2022
Q2 		$125K Sell
1,283
-87
-6% -$8.03K 0.01% 733
2022
Q1 		$128K Sell
1,370
-204
-13% -$17.3K 0.01% 774
2021
Q4 		$134K Buy
1,574
+173
+12% +$15.9K 0.01% 882
2021
Q3 		$134K Buy
1,401
+455
+48% +$43K 0.01% 865
2021
Q2 		$92K Buy
946
+10
+1% +$958 0.01% 1024
2021
Q1 		$91K Buy
936
+150
+19% +$15.7K 0.01% 984
2020
Q4 		$75K Buy
786
+121
+18% +$11.7K 0.01% 1006
2020
Q3 		$64K Buy
665
+377
+131% +$43.6K 0.01% 962
2020
Q2 		$35K Buy
288
+70
+32% +$7.74K ﹤0.01% 1101
2020
Q1 		$19K Sell
218
-60
-22% -$5.87K ﹤0.01% 1255
2019
Q4 		$30K Buy
278
+102
+58% +$10.7K ﹤0.01% 1129
2019
Q3 		$16K Buy
176
+24
+16% +$2.24K ﹤0.01% 1028
2019
Q2 		$13K Sell
152
-54
-26% -$4.43K ﹤0.01% 1407
2019
Q1 		$18K Buy
206
+72
+54% +$6.02K ﹤0.01% 1306
2018
Q4 		$9K Buy
134
+52
+63% +$4.98K ﹤0.01% 1460
2018
Q3 		$10K Buy
+82
New +$9.3K ﹤0.01% 1103

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Concourse Financial Group Securities's NBIX Position: Q1 2025 in Review

Concourse Financial Group Securities sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 669 shares — an estimated $98.2K sold.

Concourse Financial Group Securities first reported a position in NBIX in Q3 2018 and held it in 26 quarters. The position peaked at $134K in Q4 2021. 587 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Concourse Financial Group Securities reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Concourse Financial Group Securities sold 669 Neurocrine Biosciences shares in Q1 2025, an estimated $98.2K.
  • Concourse Financial Group Securities first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 26 quarters.
  • Concourse Financial Group Securities's Neurocrine Biosciences position peaked at $134K in Q4 2021.
  • 587 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Concourse Financial Group Securities's 13F filing for Q1 2025.